I-Mab Price & Performance (IMAB)

I-Mab has completed enrollment for the first dose expansion cohort in its Phase 1b givastomig study ahead of schedule. This trial, focused on gastric cancer treatment, evaluates the bispecific antibody in combination with standard therapies. Results from the dose escalation phase are expected later this year, signaling strong progress in clinical development.123

The biotech industry continues to endure layoffs, with notable companies like Sutro Biopharma and Atara Biotherapeutics reducing their workforce by nearly 50%. These cuts reflect ongoing challenges, including regulatory hurdles and funding constraints, as firms pivot strategies and prioritize key projects amidst a turbulent market environment.4

Following a 52-week low earlier this month, I-Mab's stock has rebounded with positive news on its gastric cancer therapy trials. The company’s strategic focus on givastomig development and leadership confidence, demonstrated by insider share purchases, have contributed to renewed investor optimism despite prior volatility.523